cognitive impairment after traumatic brain injury
Conditions
Interventions
Experimental group:The surgical plan was determined and implemented according to the specific injury degree, injury type and surgical indication of patients. After surgery, all patients were given sym
Placebo control group:The surgical plan was determined and implemented according to the specific injury degree, injury type and surgical indication of patients. After surgery, all patients were given
Sponsors
the Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Have a clear history of craniocerebral injury and have been confirmed by imaging examination such as head CT; 2. TBI patients were admitted to our hospital at the first time after injury; 3. The coma time after injury is less than 6h; 4. The age is between 35 and 60 years old, and the education level is junior high school or above; 5. After the patient's condition is relatively stable, explain the reason to the patient and his family, and with the consent of the family, draw blood and assess the scale; 6. The MMSE score of the simple mental state checklist is more than 15 points (= 15 points is severe dementia).
Exclusion criteria
Exclusion criteria: 1. Previous history of TBI, cerebrovascular disease and other intracranial diseases; 2. Patients with a history of diseases that affect cognitive function, such as drug abuse and alcoholism; 3. Those who cannot cooperate with the examination due to aphasia, irritability and other factors; 4. Other organs of the body with severe multiple injuries; 5. People who are allergic to olacetam; 6. Patients with dysphagia and unable to swallow capsules; 7. Patients who have taken olacetam within one month before admission; 8. Coma patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change cognitive function and social function of patients before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| the change of Fibroblast growth factor expression before and after treatment;the change of vascular endothelial growth factor expression before and after treatment;the change of Angiopoietin I expression before and after treatment;the change of Human growth factor expression before and after treatment;the change of Serum lipoprotein-associated phospholipase A2 expression before and after treatment;the change of neuron specific enolase expression before and after treatment;the change of Whole blood viscosity expression before and after treatment; | — |
Countries
China
Contacts
Public ContactLiyi Wang
The Second Hospital of Hebei Medical University
Outcome results
None listed